

( )

:

(CHD) (CKD) : \_\_\_\_\_

: \_\_\_\_\_

(GFR)

CKD

CKD

: \_\_\_\_\_

Q

CKD

CKD

% / .

CKD

Q

(p < / ) % /

. % /

% / CKD

CKD

CKD

: \_\_\_\_\_

/

Q

:

/ / :

/ / :

/ / :

%

%

%

%

:

( )

(ESRD)

CKD

%

CKD

%

ESRD

ESRD

)

(

CKD

CKD

(TLGS)

TLGS

TLGS

mL/min/

m<sup>2</sup>

(

)

%

Cardioscan PC-1200

)

CKD

( )

(

i- Multiple trials

CKD

%

( :

(

( )

ADA

JNC\_VII

(SPSS Inc,

(GFR)

Chigoca IL)

t

/

iv

iii

CKD

/ p .

<sup>ii</sup>(K/DOQI)

( mL/min/ / m ) GFR :

mL/min/ / m GFR :

m GFR :

m GFR : mL/min/ /

m GFR : mL/min/ /

.ESRD mL/min/ /

/ ± / / ± /

% /

% /

mg/dL

% / % / % /

ESRD

% /

%

% /

B

HDL-C

mL/min/ / m

LDL-C

( )

mg/dL

CKD

)

( )

CKD

(

mL/min/ / m GFR

( ) (p< / )

)

(

iii- Odds ratio

iv- Logistic Regression Analysis

i- Cockcroft-Gault

ii- Kidney Disease Outcomes Quality Initiative

	HDL-C	(p= /	CKD
	mL/min/ / m	GFR	
	LDL-c	( mg/dL	
(p< /	mg/dL	)	
CKD			± / ( )
GFR	/		( )
/ / )	mL/min/ / m		± ( )
(p< /			± ( )
(% ) CKD			/ ± / ( )
(% / ) CKD			/ ( )
			*( )
			†( )
<b>DM CKD</b>			± ( )
			± ( )
			± ( ) HDL Cholesterol
			± ( ) LDL Cholesterol
	CKD		/ ± / ( )
			/ ± / m)(mL/min/1.73
(p< / % / % / )			/ ( )
/ / )			/ ( )
)	(p< /		/ ( )
	(p= / mg/dL		/ ( )
(p< / mg/dL	)		/ ( )
	CKD		/ ( )
HDL-C	CKD		/ ( ) ACE
			( )
mg/dL	)		( )
	LDL-c	(p< /	/ ( )
	( ) ( mg/dL)		/ ( )

\*

JNC-VII

†

CKD

(% / )

( )

mL/min/ / m GFR

CKD

% /

(% / ) CKD

GFR

CKD

mg/dL

)

mL/min/ / m

ECG

( / )	( / )	( / )	
( / )	( / )	*( / )	≤
( / )	( / )	( / )	
( / )	( / )	( / )	
( / )	( / )	( / )	

\*

			( )
± †	±		( )
/	/		( )
± §	±	( )	
± †	±	( )	
/ ± / †	/ ± /	( )	
/	/	( )	
/	/	( )	
/	/	( ) <sup>†</sup>	
± †	±	( )	
± §	±	( )	
± †	±	( )	HDL Cholesterol
±	±	( )	LDL Cholesterol
/ ± / †	/ ± /	( )	
/ ± / †	/ ± /	(mL/min/1.73 m)	
/	/	( )	
/	/	( )	
/	/	( )	
/	/	( )	ACE
/	/	( )	
/	/	( )	

.p< / § p< / † JNC-VII

†

\*

%  
% / CKD

( ) (p= / )

					( )
					( )
/ †		/		( )	
/ †		/		( ) *	
†				( )	
‡				( )	
†				( )	HDL
				( )	LDL
.p< / ‡ p< / † JNC-VII *					

**Q**

( / )	( / )	( / )	*( )	
	††{( / ) }			
( / )	†( / )	( / )	( / )	Q
	†{( / ) }			
"	"	"	†	"
				‡

(% CI / / ) / odds ratio

( )

% /

% / CKD

**(Odds Ratio)**

**Q**

CKD

CKD

% /

Q

% /

CKD

Q

( )

CKD

%	Odds Ratio
/ / *	/
/ /	/
/ /	/
/ / *	/
/ / *	/
/ / *	/
/ /	/

LDL-c

HDL-C

% / )

% /

(% /

CKD

% /

% /

Q

/ / ) /

Q

CKD (% CI

(% CI / / ) /

DM

(% CI / / ) /

LDL

p< / \*



---

## References

1. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. *Am J Kidney Dis* 1998;32: 853-906.
2. Murphy SW. Management of heart failure and coronary artery disease in patients with chronic kidney disease. *Semin Dial* 2003; 16: 165-72.
3. U.S. Renal Data System: USRDS 1998 Annual Data report: Bethesda, MD: national Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease, August 1998.
4. Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P, Cartier P, et al. Canadian Hemodialysis Morbidity Study. *Am J Kidney Dis* 1992; 19: 214-34.
5. Murphy SW, Foley RN, Parfrey PS. Screening and treatment for cardiovascular disease in patients with chronic renal disease. *Am J Kidney Dis* 1998; 32: Suppl 3: S184-99.
6. De Lemos JA, Hillis LD. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. *J Am Soc Nephrol* 1996; 7: 2044-54.
7. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Cardiovascular disease risk status in elderly persons with renal insufficiency. *Kidney Int* 2002; 62: 997-1004.
8. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. *Kidney Int* 2003; 63: 1121-9.
9. Pinkau T, Hilgers KF, Veelken R, Mann JF. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? *J Am Soc Nephrol* 2004; 15: 517-23.
10. Culletton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. *Kidney Int* 1999; 56: 2214-9.
11. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; 20: 1183-97.
12. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993; 16: 434-44.
13. Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998; 339: 229-34.
14. Azizi F. Diabetes mellitus in Islamic Republic of Iran. *IDF Bulletin* 1996; 41: 38-9.
15. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). *Soz Praventivmed*. 2002; 47: 408-26.
16. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med* 2003; 139:137-47.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39: Suppl 1: 17-31.
18. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination survey. *Am J Kidney Dis* 2003; 41:1-12.
19. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000; 342: 145-53.
20. Azizi F, Rahmani M, Emami H, Madjid M. Tehran Lipid and Glucose Study: rationale and design. *CVD Prevention* 2000; 3: 242-7.
21. Azizi F, Ghanbarian A, Madjid M, Rahmani M. Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid and Glucose Study (TLGS), 1999-2000. *J Hum Hypertens* 2002; 16: 305-12.
22. Azizi F, Rashidi A, Ghanbarian A, Madjid M. Is systolic blood pressure sufficient for classification of blood pressure and determination of hypertension based on JNC-VI in an Iranian adult population? Tehran lipid and glucose study (TLGS). *J Hum Hypertens* 2003; 17: 287-91.
23. Christiansen DH, Husking JD, Dannenberg AL, Williams OD. Computer-assisted data collection in multicenter epidemiologic research: the Atherosclerosis Risk in Communities Study. *Control Clin Trials* 1990; 11: 101-15.
24. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurements and Classification. Boston, MA: John Wright PCG Inc; 1982.
25. Quality assurance and quality control. In: Atherosclerosis Risk in Communities Operations Manual. Chapel Hill, NC: ARIC Coordinating Center; 1997.
26. Hemingway H, Shipley M, Macfarlane P, Marmot M. Impact of socioeconomic status on coronary mortality in people with symptoms, electrocardiographic abnormalities, both or neither: the original Whitehall study 25 year follow up. *J Epidemiol Community Health* 2000 ; 54: 510-6.
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the



- Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003; 42: 1206-52.
28. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; 18: 499-502.
  29. World Health Organization. Guideline for controlling and monitoring. *The Tobacco Epidemic 1998a*, Geneva.
  30. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. *Circulation* 2004; 110: 1557-63.
  31. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation* 2003; 108: 2154-69.
  32. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. *Ann Intern Med* 2001; 134: 629-36.
  33. Szczech LA, Best PJ, Crowley E, Brooks MM, Berger PB, Bittner V, et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. *Circulation* 2002; 105: 2253-8.
  34. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. *Am J Kidney Dis* 2001; 38: 1398-407.
  35. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004; 351: 1296-305.
  36. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. *Am J Kidney Dis* 2003; 42: 677-84.
  37. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD. Heart and Estrogen/progestin Replacement Study (HERS) Investigators. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. *J Am Coll Cardiol* 2001; 38: 705-11.
  38. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. *Stroke* 1997; 28: 557-63.
  39. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. *Kidney Int* 2002; 61: 1486-94.
  40. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? *Nephrol Dial Transplant* 2001; 16: 1042-6.
  41. Gupta R, Birnbaum Y, Uretsky BF. The renal patient with coronary artery disease: current concepts and dilemmas. *J Am Coll Cardiol* 2004; 44: 1343-53.
  42. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. *Am J Kidney Dis* 1996; 27: 84-91.